Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Jan;95(1):40-3.
doi: 10.1111/j.1349-7006.2004.tb03168.x.

Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer

Jun-ichi Akahira  1 , Youko Sugihashi, Kiyoshi Ito, Hitoshi Niikura, Kunihiro Okamura, Nobuo Yaegashi
Affiliations
Comparative Study

Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer

Jun-ichi Akahira et al. Cancer Sci. 2004 Jan.

Abstract

Gene silencing associated with aberrant DNA methylation of promoter CpG islands is one mechanism through which tumor suppressor genes are inactivated in human cancers. TMS1 (target of methylation-induced silencing) is a CpG island-associated gene that functions in the regulation of apoptosis. In this study, we examined the DNA methylation status of the TMS1 promoter in ovarian cancer cell lines and tissues by methylation-specific PCR (MSP) and its mRNA expression by reverse transcription and quantitative PCR. Aberrant methylation of TMS1 was present in 7/12 ovarian cancer cell lines and 8/20 primary ovarian cancer tissues. The median value of relative TMS1 gene expression in cancers with methylation (0.15) was significantly lower than that in cancers without methylation (13.9) (P < 0.001). The expression of the TMS1 gene was relatively high (48.5) in the normal ovarian cDNA library. TMS1 gene expression was restored by treatment with the demethylating agent 5-aza-2'-deoxycitidine in the OV90 cell line, which lacks the TMS1 transcript. Our results suggest that aberrant methylation of TMS1 may play a role in the pathogenesis of ovarian cancer.

PubMed Disclaimer

References

    1. Miki Y, Swensen J, Shattuck‐Eidens D, Futreal PA, Harshman K, Tartigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71. - PubMed
    1. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rices C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, , Deborah FordTonin P , Bishop DT, Spurr NK, Ponder Bruce AJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–92. - PubMed
    1. Newman B, Millikan RC, King MC. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev 1997; 19: 69–79. - PubMed
    1. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457–62. - PMC - PubMed
    1. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription Trends Genet 1997; 13: 444–9. - PubMed

Publication types